8-K: Neumora's NMRA-511 Shows Unsurpassed Efficacy in AD Agitation

Neumora Therapeutics presents positive Phase 1b data for NMRA-511, demonstrating strong efficacy and favorable tolerability in Alzheimer's disease agitation, particularly in patients with elevated anxiety.

Summary

• NMRA-511 Phase 1b study results were presented at the Guggenheim Emerging Outlook: Biotech Summit 2026.
• The study demonstrated unsurpassed efficacy in patients with Alzheimer's disease (AD) agitation, especially those with elevated anxiety (RAID score ≥ 12).
• NMRA-511 was well tolerated, with typically mild to moderate treatment-emergent adverse events (TEAEs) and low treatment discontinuations (2.5%).
• The CMAI effect size for NMRA-511 was similar to Auvelity in the total population and unsurpassed in patients with elevated anxiety.
• The study was designed as signal-seeking and was not powered to demonstrate statistical significance, but the observed effect sizes will inform future development.
• One serious adverse event of asthenia (general weakness) was reported, which resolved by the time of discharge and was maintained at study follow-up.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive update, showcasing promising early-stage clinical data for a drug targeting a significant unmet medical need, with favorable efficacy and safety profiles.

Positives

• NMRA-511 demonstrated unsurpassed efficacy in patients with AD agitation, particularly in the pre-specified elevated anxiety sub-population (RAID score ≥ 12).
• The drug exhibited a favorable tolerability and safety profile, with typically mild to moderate treatment-emergent adverse events (TEAEs).
• Treatment discontinuations due to TEAEs were low at 2.5%.
• There is an opportunity to evaluate higher doses of NMRA-511 based on its favorable tolerability profile.
• Consistent treatment effect was observed across a range of measures, including CMAI Total Score, CMAI Aggressive Behaviors Score, CGI-S Agitation, and NPI Agitation/Aggression.
• NMRA-511 achieved a clinically meaningful 15.7-point reduction in CMAI total score at Week 8.
• The results suggest an opportunity for convenient dosing with an XR formulation.
• Future studies can be enriched for elevated anxiety, a strategy not employed in this Phase 1b study, potentially enhancing future outcomes.

Negatives

• The Phase 1b study was not powered to demonstrate statistical significance.
• Comparisons to Auvelity and Rexulti are for illustrative purposes only and are not based on head-to-head trials, with acknowledged differences in compounds, trial designs, and other factors.
• Two placebo patients were excluded from the modified analysis set due to rater change driving outlier data (>3 standard deviations from the mean).

Risks

• Risks related to the inherent uncertainty of clinical drug development and the unpredictability and lengthy process for obtaining regulatory approvals.
• Risks related to the timely initiation and enrollment in clinical trials.
• Risks related to reliance on third parties, including contract research organizations.
• Risks related to serious or undesirable side effects of therapeutic candidates.
• Risks related to the ability to utilize and protect intellectual property rights.
• Risks related to the sufficiency of capital resources to fund operations.

Future Outlook

Neumora intends to redefine neuroscience drug development by bringing forward the next generation of novel therapies that offer improved treatment outcomes and quality of life for patients. The company sees an opportunity to evaluate higher doses of NMRA-511 and to enrich future studies for elevated anxiety, which was not done in this Phase 1b study, to further enhance potential outcomes.

Management Comments

• Neumora's intention to redefine neuroscience drug development by bringing forward the next generation of novel therapies that offer improved treatment outcomes and quality of life for patients.
• NMRA-511 demonstrated unsurpassed efficacy in patients with AD agitation.
• NMRA-511 was safe and generally well tolerated.

Industry Context

StockSavvy.ai notes that Alzheimer's disease agitation represents a large and growing health burden, with millions of U.S. adults affected and over 70% experiencing agitation at some point in their disease. There is a significant unmet medical need for therapies that reduce agitation with improved tolerability and safety profiles, as the only currently approved therapy carries a boxed warning for mortality in elderly people with dementia-related psychosis. NMRA-511 aims to address this gap with a differentiated benefit/risk profile, potentially offering a new and better-tolerated treatment option.

Comparison to Industry Standards

• NMRA-511's CMAI total score effect size in the total population (0.20-0.23) is similar to Auvelity (~0.2-0.25) but lower than Rexulti (0.35).
• In the pre-specified elevated anxiety sub-population (RAID score ≥ 12), NMRA-511 demonstrated an unsurpassed CMAI total score effect size (0.51-0.64), which is significantly higher than Rexulti (0.35) and Auvelity (~0.2-0.25).
• For CMAI Aggressive Behaviors Score in the elevated anxiety population, NMRA-511 showed an effect size of 0.82-1.1, compared to Rexulti's 0.33.
• For CGI-S Agitation in the elevated anxiety population, NMRA-511 showed an effect size of 0.38-0.78, compared to Rexulti's 0.31.
• For NPI Agitation/Aggression in the elevated anxiety population, NMRA-511 showed an effect size of 0.42-0.46, compared to Rexulti's 0.39 (NPI-nursing home) and Auvelity's not reported.
• It is important to note that Rexulti and Auvelity studies were enriched with an NPI-AA domain cutoff of 4 at baseline, whereas the NMRA-511 Phase 1b study included no such enrichment, suggesting NMRA-511's strong results were achieved without pre-selecting for higher baseline agitation.

Stakeholder Impact

• Shareholders: Positive impact due to promising clinical trial results, potentially increasing the company's valuation and future revenue prospects.
• Patients (with AD agitation): Potential for a new, effective, and well-tolerated treatment option to improve quality of life and reduce agitation symptoms.
• Caregivers: Potential for improved quality of life due to reduced patient agitation and associated burden.

Next Steps

• Potential evaluation of higher doses of NMRA-511 in future studies.
• Opportunity to enrich future studies for elevated anxiety to potentially enhance treatment effects.
• Further development of NMRA-511 in Alzheimer's disease agitation.

Key Dates

Recommendation

The Phase 1b results for NMRA-511 in Alzheimer's disease agitation are highly encouraging, demonstrating strong efficacy, particularly in the elevated anxiety sub-population, and a favorable safety profile. The 'unsurpassed efficacy' claim, even in a signal-seeking study, suggests significant potential in a market with high unmet need and limited well-tolerated options. This positive early-stage data significantly de-risks the program and could lead to substantial value creation if confirmed in later-stage trials, making it an attractive investment opportunity.

Keywords

Neumora Therapeutics, NMRA-511, Alzheimer's Disease Agitation, AD Agitation, Biotech, Clinical Trial, Phase 1b, Neuroscience, Drug Development, CMAI, Guggenheim Biotech Summit